DK1594970T3 - Fremgangsmåde til generering af rekombinant MVA - Google Patents

Fremgangsmåde til generering af rekombinant MVA

Info

Publication number
DK1594970T3
DK1594970T3 DK04712013T DK04712013T DK1594970T3 DK 1594970 T3 DK1594970 T3 DK 1594970T3 DK 04712013 T DK04712013 T DK 04712013T DK 04712013 T DK04712013 T DK 04712013T DK 1594970 T3 DK1594970 T3 DK 1594970T3
Authority
DK
Denmark
Prior art keywords
recombinant mva
mva
generating recombinant
dna
generation
Prior art date
Application number
DK04712013T
Other languages
Danish (da)
English (en)
Inventor
Caroline Staib
Marianne Loewel
Volker Erfle
Gerd Sutter
Original Assignee
Helmholtz Zentrum Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum Muenchen filed Critical Helmholtz Zentrum Muenchen
Application granted granted Critical
Publication of DK1594970T3 publication Critical patent/DK1594970T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK04712013T 2003-02-18 2004-02-18 Fremgangsmåde til generering af rekombinant MVA DK1594970T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44823103P 2003-02-18 2003-02-18
PCT/EP2004/001554 WO2004074493A1 (en) 2003-02-18 2004-02-18 Recombinant mva and method for generation thereof

Publications (1)

Publication Number Publication Date
DK1594970T3 true DK1594970T3 (da) 2008-11-17

Family

ID=32908561

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04712013T DK1594970T3 (da) 2003-02-18 2004-02-18 Fremgangsmåde til generering af rekombinant MVA

Country Status (8)

Country Link
US (1) US20060002896A1 (enExample)
EP (1) EP1594970B1 (enExample)
JP (2) JP4686443B2 (enExample)
CN (1) CN1723285B (enExample)
AT (1) ATE403005T1 (enExample)
DE (1) DE602004015418D1 (enExample)
DK (1) DK1594970T3 (enExample)
WO (1) WO2004074493A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
AU2003297499A1 (en) 2002-12-23 2004-07-22 City Of Hope Modified vaccinia ankara expressing p53 in cancer immunotherapy
EP2199400A1 (en) 2008-12-22 2010-06-23 Emergent Product Development Germany GmbH Single recombination system and methods of use
CN102559611B (zh) * 2011-06-23 2015-04-22 江苏省农业科学院 一种无筛选标记的双表达重组mva病毒及其构建方法
US10736962B2 (en) * 2016-02-25 2020-08-11 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
NZ750578A (en) * 2016-08-19 2023-05-26 Sementis Ltd Viral vaccines
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP3928789A1 (en) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
WO2022269003A1 (en) 2021-06-23 2022-12-29 Consejo Superior De Investigaciones Cientificas MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN
EP4108257A1 (en) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
EP4316514A1 (en) 2022-08-03 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vectors and their use as vaccine against sars-cov-2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015672A1 (en) * 1991-03-07 1992-09-17 Virogenetics Corporation Genetically engineered vaccine strain
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
EP1012276A2 (en) * 1997-02-24 2000-06-28 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
BR0111366A (pt) * 2000-05-24 2003-05-20 Merial Sas Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv)
GB0111442D0 (en) * 2001-05-10 2001-07-04 Isis Innovation Method for preparing recombinant virus

Also Published As

Publication number Publication date
JP5166505B2 (ja) 2013-03-21
JP4686443B2 (ja) 2011-05-25
JP2006517795A (ja) 2006-08-03
US20060002896A1 (en) 2006-01-05
EP1594970A1 (en) 2005-11-16
CN1723285A (zh) 2006-01-18
WO2004074493A1 (en) 2004-09-02
CN1723285B (zh) 2013-01-02
DE602004015418D1 (de) 2008-09-11
JP2011055840A (ja) 2011-03-24
EP1594970B1 (en) 2008-07-30
ATE403005T1 (de) 2008-08-15

Similar Documents

Publication Publication Date Title
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
PH12019502456A1 (en) Methods for making high intensity sweeteners
PH12021550997A1 (en) Methods for making high intensity sweeteners
WO2005056759A3 (en) Methods of generating variant proteins with increased host string content and compositions thereof
DE602004028468D1 (de) Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
EA200900676A1 (ru) Ингибиторы вируса гепатита с
BRPI0817299A8 (pt) vacinas e componentes de vacina para inibição de células microbianas
NO20091845L (no) Macrocykliske peptider som hepatitt C virus-inhibitorer
MX391236B (es) Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos.
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
DK1668001T3 (da) Substituerede heteroarylbenzofuransyrer
WO2007024941A3 (en) Polyvalent vaccine
DE60117814D1 (de) Nicht-imidazol aryloxyalkylamine als h3 rezeptor liganden
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
MX2021001168A (es) Medios y metodos para el clivaje de la zearalenona.
TW200632614A (en) Voltage reference generator and method of generating a reference voltage
ATE403005T1 (de) Rekombinantes mva und verfahren zur erzeugung davon
DK1395283T3 (da) Heterolog beskyttelse induceret ved immunisering med Invaplex-vaccine
ATE321853T1 (de) Humanische pellino-polypeptide
EA200500367A1 (ru) Способы и устройства для снятия напряжений с использованием нескольких источников энергии
EA200301151A1 (ru) Вакцина против натуральной оспы
BRPI0516576A (pt) vetores quiméricos
WO2006138441A3 (en) Boost devices and methods of using them